Skip to content
‹ Back to IndustriesHealthcare

A Coronavirus Economic Update: Business Casual

With the number of coronavirus cases worldwide approaching 80,000 (most of them in China) with 35 cases already reported in the U.S., and a death toll that now tops 2,600, both American and international companies are apprehensive over the likely economic impacts, warning that reduced flows into and out of the world’s second-largest economy…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Start free

With the number of coronavirus cases worldwide approaching 80,000 (most of them in China) with 35 cases already reported in the U.S., and a death toll that now tops 2,600, both American and international companies are apprehensive over the likely economic impacts, warning that reduced flows into and out of the world’s second-largest economy will have a tangible effect on business and product availability throughout the world.

Today, there remains huge uncertainty about how widely the virus will spread and how much damage it will do. But in America, where the S&P 500 hit a new high last Wednesday, this week, after reports of people infected with the virus in the major economies of South Korea and Italy, the S&P dropped more than 7 percent. Further, on Tuesday, yields on 10-year United States Treasury bonds fell to their lowest levels on record, suggesting investors expect significant economic damage and accompanying Federal Reserve interest-rate cuts.

Taking a growing toll on the U.S. economy, Mark Zandi, Chief Economist of Moody’s Analytics, estimates the outbreak will reduce growth during the first three months of 2020 by six-tenths of a percentage point to 1.3%, chiefly through reduced travel and tourism and manufacturers who will likely export less to Asia and Europe as demand there slackens.

In this Business Casual segment, Daniel Litwin and Taylor Bagley take on the coronavirus issue, and examine the current economic impacts as well as the potential consequences should the virus spread further and make significant landfall here on our country’s shores.

“What we really need to work on now is getting accurate information, the right information about how many people have been affected by this, how we can actually contain this,” Bagley stated.

“We need to prepare for the reality that if it does hit the United States in a more aggressive way, that we’re really going to be testing our mobile workforce honestly. People are going to be working from home, schools are going to be canceled—what does that look like,” Litwin said. “So, day-to-day could change a lot and that would impact our economy substantially.”

For more Business Casual, listen live on MarketScale Radio on Wednesdays and Fridays at 9 AM CT, and follow us on Twitter at @BizCasualRadio.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512